FIRMAGON
Total Payments
$3.1M
Transactions
12,584
Doctors
3,518
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $390.31 | 22 | 22 |
| 2023 | $446.08 | 12 | 12 |
| 2022 | $23,205 | 25 | 23 |
| 2021 | $518,026 | 147 | 10 |
| 2020 | $524,018 | 750 | 571 |
| 2019 | $378,175 | 2,542 | 1,230 |
| 2018 | $793,924 | 1,340 | 818 |
| 2017 | $837,914 | 7,746 | 2,787 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.4M | 200 | 77.5% |
| Food and Beverage | $245,864 | 11,709 | 8.0% |
| Consulting Fee | $228,712 | 35 | 7.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $148,854 | 68 | 4.8% |
| Travel and Lodging | $65,121 | 227 | 2.1% |
| Education | $2,694 | 345 | 0.1% |
Payments by Type
Research
$2.4M
200 transactions
General
$691,246
12,384 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II Study of Docetaxel Before Medical Castration with Degarelix in Patients with Newly Diagnosed Metastatic Prostatic Adenocarcinoma | Ferring Pharmaceuticals Inc. | $865,805 | 0 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist | Ferring Pharmaceuticals AS | $633,204 | 0 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) | Ferring International Pharmascience Center US | $317,708 | 0 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) | Ferring Pharmaceuticals AS | $152,319 | 0 |
| Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer | Ferring Pharmaceuticals Inc. | $142,925 | 0 |
| A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer | Ferring Pharmaceuticals Inc. | $78,669 | 0 |
| Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination with Degarelix in Men with Hormone-Sensitive Prostate Cancer | Ferring Pharmaceuticals Inc. | $66,688 | 0 |
| Randomized Phase 1b2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer | Ferring Pharmaceuticals Inc. | $52,562 | 0 |
| Nivolumab and BMS-986253 combined with Degarelix for Hormone-Sensitive Prostate Cancer | Ferring Pharmaceuticals Inc. | $19,538 | 0 |
| Degarelix Acetate Prior to Radiation Therapy | Ferring Pharmaceuticals Inc. | $16,259 | 0 |
| A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma. | Ferring Pharmaceuticals Inc. | $14,283 | 0 |
| Gonadotropin LHFSH-releasing hormone GnRH Antagonists Evaluation of Beneficial Effects for Alzheimers Disease | Ferring Pharmaceuticals Inc. | $11,234 | 0 |
| Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P) | Ferring Pharmaceuticals Inc. | $7,621 | 0 |
| Randomized Phase 1b2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination with Degarelix in Men with Hormone-Sensitive Prostate Cancer | Ferring Pharmaceuticals Inc. | $6,038 | 0 |
Top Doctors Receiving Payments for FIRMAGON — Page 141
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Urology | Mt Pleasant, PA | $10.45 | 1 |
| , MD | Specialist | Edison, NJ | $10.45 | 1 |
| , M.D | Radiation Oncology | Newark, DE | $10.44 | 1 |
| , M.D | Radiation Oncology | Newark, DE | $10.44 | 1 |
| , M.D | Urology | Greenville, SC | $10.41 | 1 |
| , MD | Urology | Greensboro, NC | $10.38 | 1 |
| , MD | Urology | Gainesville, GA | $10.38 | 1 |
| , MD | Urology | Greensboro, NC | $10.37 | 1 |
| , MD | Urology | Greensboro, NC | $10.37 | 1 |
| , MD | Surgical Oncology | Buffalo, NY | $10.36 | 1 |
| , D.O | Radiation Oncology | Lake City, FL | $10.35 | 1 |
| , M.D | Hematology & Oncology | Annapolis, MD | $10.35 | 1 |
| , M.D | Medical Oncology | Lake City, FL | $10.35 | 1 |
| , MD | Medical Oncology | Lake City, FL | $10.35 | 1 |
| , M.D | Anesthesiology | Rockville, MD | $10.32 | 1 |
| , MD | Urology | Springfield, OR | $10.32 | 1 |
| , M.D | Urology | Houston, TX | $10.24 | 1 |
| , M.D | Urology | West Jordan, UT | $9.00 | 1 |
| , MD | Surgery | Fresno, CA | $5.42 | 1 |
Ad
Manufacturing Companies
- Ferring Pharmaceuticals Inc. $1.9M
- Ferring Pharmaceuticals AS $785,523
- Ferring International Pharmascience Center US $326,464
- Ferring Pharmaceuticals LTD $17,514
- Ferring Sendirian Berhad $16,358
- Ferring International Center SA $4,975
- Ferring Pharmaceuticals (Asia) Co. Ltd. $3,500
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 3,518
- Transactions 12,584
About FIRMAGON
FIRMAGON is a drug associated with $3.1M in payments to 3,518 healthcare providers, recorded across 12,584 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $390.31 was paid across 22 transactions to 22 doctors.
The most common payment nature for FIRMAGON is "Unspecified" ($2.4M, 77.5% of total).
FIRMAGON is associated with 14 research studies, including "A Phase II Study of Docetaxel Before Medical Castration with Degarelix in Patients with Newly Diagnosed Metastatic Prostatic Adenocarcinoma" ($865,805).